Genentech initiates study on cevostamab and elranatamab for relapsed/refractory multiple myeloma
The initiation of this trial by Genentech is significant as it explores a new combination therapy for relapsed/refractory multiple myeloma, a critical area in oncology. Positive results could strengthen Genentech's competitive position and influence treatment protocols in this therapeutic area.
Phase III
Oncology / Multiple Myeloma
Status
Active
Sponsor
Roche
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
The initiation of this trial by Genentech is significant as it explores a new combination therapy for relapsed/refractory multiple myeloma, a critical area in oncology. Positive results could strengthen Genentech's competitive position and influence treatment protocols in this therapeutic area.
Why it matters
The initiation of this trial by Genentech is significant as it explores a new combination therapy for relapsed/refractory multiple myeloma, a critical area in oncology. Positive results could strengthen Genentech's competitive position and influence treatment protocols in this therapeutic area.
What changed
Trial Update
Analysis
Genentech is evaluating the safety and pharmacokinetics of cevostamab in combination with elranatamab for R/R MM.
The initiation of this trial by Genentech is significant as it explores a new combination therapy for relapsed/refractory multiple myeloma, a critical area in oncology. Positive results could strengthen Genentech's competitive position and influence treatment protocols in this therapeutic area.
Monitor for results from the safety lead-in stage and the determination of the recommended Phase II regimen.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.